Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia

Blood

Volumn 121, Issue 21, 2013, Pages 4348-4354

  Uckun, Fatih M ^a,c   Qazi, Sanjive ^a,d   Cely, Ingrid ^a   Sahin, Kazim ^e   Shahidzadeh, Anoush ^a   Ozercan, Ibrahim ^f   Yin, Qian ^g   Gaynon, Paul ^a,b   Termuhlen, Amanda ^b,h   Cheng, Jianjun ^g   Yiv, Seang ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b Division of Hematology Oncology   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GUSTAVUS ADOLPHUS COLLEGE   (United States)

^e Faculty of Science   (Turkey)

^f FIRAT UNIVERSITY   (Turkey)

^g University of Illinois at Urbana Champaign   (United States)

^h MILLER CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS (9 O DIHYDROQUINIDINYL) PHTHALAZINE; ANTILEUKEMIC AGENT; HYDROQUINIDINE 1,4 PHATHALAZINEDIYL DIETHER; PROTEIN KINASE SYK INHIBITOR; UNCLASSIFIED DRUG; 1,4 BIS(9 O DIHYDROQUINIDINYL)PHTHALAZINE HYDROQUINIDINE 1,4 PHATHALAZINEDIYL DIETHER; 1,4-BIS(9-O DIHYDROQUINIDINYL)PHTHALAZINE HYDROQUINIDINE 1,4-PHATHALAZINEDIYL DIETHER; DRUG CARRIER; LIPOSOME; NANOSPHERE; PHTHALAZINE DERIVATIVE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BLAST CELL; CANCER PATIENT; CELL SURVIVAL; CLONOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; ELIMINATION HALF-LIFE; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOSCALE LIPOSOMAL FORMULATION; NONHUMAN; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; TUMOR XENOGRAFT; ANIMAL; CHILD; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANIMALS; APOPTOSIS; CHILD; DRUG CARRIERS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOSOMES; MICE; MICE, INBRED NOD; MICE, SCID; NANOSPHERES; PHTHALAZINES; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MLCS; MLOWN;

EID: 84880425231     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-470633     Document Type: Article

References (23)

1. Reaman GH, Smith FO. Childhood Leukemia: A Practical Handbook. Heidelberg, Berlin: Springer Verlag; 2011
2. Pui C-H, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5): 551-565.
3. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005; 131(5):579-587.
4. Gaynon PS, Harris RE, Altman AJ, et al. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group study CCG-1941. J Clin Oncol. 2006;24(19): 3150-3156.
5. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008;111(5): 2548-2555.
6. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995;378(6554):303-306.
7. Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
8. Uckun FM, Qazi S. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas. Expert Rev Anticancer Ther. 2010; 10(9):1407-1418.
9. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA. 2010; 107(7):2902-2907.
10. Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br J Haematol. 2010;149(4):508-517.
11. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
12. Karve S, Werner ME, Sukumar R, et al. Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proc Natl Acad Sci USA. 2012;109(21):8230-8235.
13. Yiv SH, Uckun FM. Lipid spheres as attractive nanoscale drug delivery platforms for cancer therapy. J Nanomed Nanotechnol. 2012;3(1):128.
14. Kong Y, Yoshida S, Saito Y, et al. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL. Leukemia. 2008; 22(6):1207-1213.
15. le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008; 14(1):47-58.
16. Meyer LH, Eckhoff SM, Queudeville M, et al. Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell. 2011;19(2):206-217.
17. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat. 2009;19(10):1361-1376.
18. D’Cruz O, Uckun FM. [Review] Targeting spleen tyrosine kinase (SYK) for treatment of human disease. Journal of Pharmaceutics & Drug Delivery Research. 2012;1:2. http://www. scitechnol.com/JPDDR/JPDDR-1-107.pdf
19. D’Cruz OJ, Uckun FM. Protein kinase inhibitors against malignant lymphoma. Expert Opin Pharmacother. 2013;14(6): 707-721.
20. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Q Rev Biophys. 2009;42(1): 1-40.
21. Ye G, Tiwari R, Parang K. Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs. 2008;9(6): 605-613.
22. Marsilje TH, Milkiewicz KL, Hangauer DG. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg Med Chem Lett. 2000; 10(5):477-481.
23. Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene. 2001;20(30): 3969-3978.